DEF: Stran & Company Faces Governance Scrutiny Amidst Auditor Instability and Internal Control Weaknesses

Sentiment:

Definitive Proxy Statement 11 July 2025 8:00 AM

Stran & Company, Inc. will hold a combined 2024 and 2025 Annual Meeting to elect directors and ratify its new independent accounting firm, CBIZ CPAs P.C., following multiple auditor changes and disclosures of material weaknesses in internal financial controls.

Delay expectedThe company explicitly stated, 'We did not hold an annual meeting of stockholders during 2024,' and is instead holding a 'Combined 2024 and 2025 Annual Meeting of Stockholders' on July 25, 2025, indicating a delay in its regular annual meeting schedule.

Worse than expectedThe company disclosed six material weaknesses in its internal control over financial reporting for fiscal years 2024 and 2023, indicating significant deficiencies in financial oversight and reporting processes.The company experienced multiple changes in its independent registered public accounting firm, including the dismissal of BF Borgers CPA PC due to an SEC order and the subsequent resignation of Marcum LLP, which suggests instability and potential issues with auditability.Performance targets for executive cash and equity bonuses for the Chief Financial Officer, Vice President of Growth and Strategic Initiatives, and Chief Information Officer were not met for fiscal year 2024, implying underperformance against internal goals.A related party transaction with a former director's company has a substantial outstanding balance of $1,001,000 as of December 31, 2024, accruing 8% annual interest, which could pose a collection risk and impact liquidity.

Summary

Stran & Company, Inc. is convening a Combined 2024 and 2025 Annual Meeting of Stockholders on July 25, 2025, to elect six director nominees and ratify the appointment of CBIZ CPAs P.C. as its independent registered public accounting firm for the fiscal year ending December 31, 2025.
The company dismissed BF Borgers CPA PC on May 13, 2024, due to an SEC order against the firm, and subsequently engaged Marcum LLP on June 15, 2024.
Marcum LLP resigned on April 30, 2025, and CBIZ CPAs P.C. was engaged on the same day, following CBIZ's acquisition of Marcum LLP's attest business on November 1, 2024.
Marcum LLP's audit reports for fiscal years 2024 and 2023 identified material weaknesses in internal control over financial reporting, including issues with complex accounting transactions, management review processes, income tax provision, accounts receivable, unearned revenue, freight charges, inventory, cost of sales, related party transaction disclosure, and IT general controls.
Audit fees billed by Marcum LLP were $370,250 for 2024 and $225,000 for 2023.
As of July 9, 2025, Andrew Stranberg, Executive Chairman, beneficially owned 29.3% of common stock, and Andrew Shape, CEO, owned 19.8%. All directors and executive officers collectively owned 49.6% of the outstanding common stock.
The company did not hold an annual meeting of stockholders during 2024.
Executive compensation for 2024 included Andrew Shape's salary of $400,000 and Andrew Stranberg's salary of $500,000. Ian Wall, CIO, received $281,566 in total compensation for 2024, including option awards.
Performance targets for cash and equity bonuses for the CFO (David Browner), VP of Growth and Strategic Initiatives (John Audibert), and CIO (Ian Wall) were not met for fiscal year 2024.
A related party transaction with Innovative Genetics Inc., majority-owned by former director Alejandro Tani, had an outstanding balance of $1,001,000 as of December 31, 2024, accruing 8% annual interest for past due payments, with Mr. Tani providing a personal guaranty.
Remedial compensation totaling $34,146 in cash was paid to former non-employee directors Travis McCourt, Alejandro Tani, and Ashley L. Marshall due to an administrative oversight in stock grants. Alan Chippindale received $11,382 in cash and 20,000 shares for the same reason.

Sentiment

Score: 3

Explanation: The sentiment is predominantly negative due to significant concerns regarding financial reporting integrity, evidenced by multiple auditor changes and the disclosure of six material weaknesses in internal controls. The large, outstanding related party transaction balance and the missed 2024 annual meeting further contribute to a cautious outlook, outweighing the positives of new independent directors and a clawback policy.

Positives

The Board of Directors consists of a majority of independent directors (4 out of 6), enhancing oversight.
New directors Mark Charles Adams, Sarah L. Cummins, and Brian M. Posner bring diverse experience in media, publishing, private equity, business development, strategic partnerships, brand management, and public company finance/audit committee expertise.
The company adopted a Clawback Policy in November 2023, aligning with Nasdaq rules for recovering erroneously awarded incentive-based compensation.
The company maintains a separate Executive Chairman and CEO, which is intended to provide a balance to the Chief Executive Officer's role.

Negatives

The company experienced multiple changes in its independent registered public accounting firm, dismissing BF Borgers CPA PC due to an SEC order and then Marcum LLP resigning, indicating instability in financial oversight.
Marcum LLP identified six material weaknesses in the company's internal control over financial reporting for fiscal years 2024 and 2023, including issues with complex accounting transactions, management review, income tax provision, accounts receivable, unearned revenue, freight charges, inventory, cost of sales, related party transaction disclosure, and IT general controls.
The annual performance targets for cash and equity bonuses for the Chief Financial Officer, Vice President of Growth and Strategic Initiatives, and Chief Information Officer were not met for fiscal year 2024.
A significant related party transaction with Innovative Genetics Inc., involving a former director, has an outstanding balance of $1,001,000 as of December 31, 2024, with 8% annual interest accruing on past due payments, raising concerns about collectability and potential financial strain.
The company did not hold an annual meeting of stockholders during 2024, combining it with the 2025 meeting, which could be perceived as a lapse in regular corporate governance.

Risks

Material weaknesses in internal control over financial reporting pose a significant risk to the accuracy and reliability of financial statements, potentially leading to misstatements or restatements.
The instability and changes in independent registered public accounting firms could signal underlying issues with financial reporting practices or a lack of auditor confidence.
The substantial outstanding balance and accruing interest from the related party transaction with Innovative Genetics Inc., coupled with the personal guaranty from a former director, presents a credit risk and potential for future write-offs if not collected.
Failure to meet performance targets for executive compensation in 2024 may indicate underperformance relative to internal expectations, potentially impacting future executive motivation or retention.
The absence of an annual meeting in 2024 and the combined meeting in 2025 could raise questions about corporate governance practices and shareholder engagement.

Future Outlook

The document primarily focuses on corporate governance matters for the upcoming combined 2024 and 2025 Annual Meeting. It does not provide specific forward-looking statements or financial guidance regarding the company's future performance, revenue, or profitability. It outlines the process for future stockholder proposals and universal proxy notices for the 2026 Annual Meeting.

Management Comments

The Board recommends a vote FOR each of the six nominees to the Board.
The Board recommends a vote FOR ratification of the appointment of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.

Industry Context

The document provides limited industry context, primarily through the qualifications of new and existing directors, such as Alan Chippindale's leading role in the promotional products industry and Sarah L. Cummins' extensive experience in sports, entertainment, and consumer products. It does not offer a broader analysis of current industry trends or the company's competitive positioning within these sectors.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Director	Travis McCourt		2025-06-01	Cessation of directorship
Director	Alejandro Tani		2025-06-01	Cessation of directorship
Director	Ashley L. Marshall		2025-06-01	Cessation of directorship
Director		Mark Charles Adams	2025-06-20	Election to the Board
Director		Sarah L. Cummins	2025-06-20	Election to the Board
Director		Brian M. Posner	2025-07-08	Election to the Board
Chief Information Officer		Ian Wall	2024-01-01	Appointment to position

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Policy Adoption	Adoption of the Clawback Policy on November 2, 2023, in accordance with Nasdaq rules, allowing for the recovery of erroneously awarded incentive-based compensation in the event of an accounting restatement.	2023-11-02	Enhances corporate accountability and aligns executive incentives with accurate financial reporting, potentially improving investor confidence.
Committee Structure	The Board maintains four committees: Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee, and Disclosure Controls and Procedures Committee, each operating under a written charter.		Provides structured oversight for key areas including financial reporting, executive compensation, director nominations, and disclosure accuracy.
Leadership Structure	The company maintains separate Executive Chairman (Andrew Stranberg) and Chief Executive Officer (Andrew Shape) roles, with the Executive Chairman acting as a balance to the CEO.		Aims to provide independent oversight of management, although the Bylaws allow for flexibility to combine these positions if deemed in the best long-term interests of stockholders.

Legal Proceedings

No involvement in certain legal proceedings described in subparagraph (f) of Item 401 of Regulation S-K by any directors, director nominees, or executive officers during the past ten years.
No material proceedings to which any director, director nominee, executive officer, affiliate, or beneficial owner of more than 5% of voting securities is a party adverse to the Company or has a material interest adverse to the Company.

Related Party Transactions

A Branded Packaging Agreement with Innovative Genetics Inc., majority-owned by former director Alejandro Tani, had an outstanding balance of $1,001,000 as of December 31, 2024, plus related shipping costs with a 30% markup and duties/taxes at cost. An 8% annual interest began to accrue on the past due balance as of December 31, 2024. Mr. Tani personally guaranteed the payment obligations.
Payments to Engage & Excel Enterprises Inc., where director Alan Chippindale is President, totaled $7,500 for recruiting fees and $18,848 for consulting fees in 2024 related to the T R Miller assets acquisition. In 2023, payments were $17,500 for recruiting fees and $20,000 for consulting fees for the same acquisition. The company also agreed to pay 1.5% of the T R Miller assets' contribution margin for two years.
Kapstone Partners, LLC, which provided sales and operational consulting services, resulted in Sarah L. Cummins (a director elected in June 2025) being awarded 23,043 shares of common stock on January 29, 2024, valued at $30,000, based on services provided in 2023.
Open-market purchases of common stock by related persons in 2023 included: Alan Chippindale (8,000 shares at $1.4667), Andrew Stranberg (10,560 shares at $1.0995, 9,934.436 shares at $1.5099, 2,695.707 shares at $1.4838), John Audibert (3,250 shares at $1.4723), and Ashley L. Marshall (760 shares at $1.26).

Stakeholder Impact

Shareholders: Directly impacted by the election of directors, ratification of the accounting firm, and the transparency of financial controls and related party transactions. The material weaknesses and auditor changes could affect investor confidence and share valuation.
Employees: Executive officers' compensation is detailed, including performance-based bonuses that were not met for 2024, potentially impacting morale or future performance incentives. The Clawback Policy affects executive compensation recovery.
Customers/Suppliers: The related party transaction with Innovative Genetics Inc. highlights a specific business relationship, though the direct impact on other customers/suppliers is not detailed.
Creditors: The outstanding balance from the Innovative Genetics transaction and the general financial health implied by internal control weaknesses could be of interest to creditors.
Regulatory Authorities: The SEC's action against a former auditor (BF Borgers) and the company's subsequent disclosures of material weaknesses demonstrate ongoing regulatory scrutiny and compliance requirements.

Next Steps

Hold the Combined 2024 and 2025 Annual Meeting of Stockholders on July 25, 2025, to elect directors and ratify the independent accounting firm.
File a Current Report on Form 8-K with the SEC within four business days after the Annual Meeting to disclose preliminary or final voting results.
Prepare for the 2026 Annual Meeting, with stockholder proposal deadlines for Rule 14a-8 by February 5, 2026, and universal proxy notice by May 26, 2026.

Key Dates

Date	Description
1987-09-01	Alan Chippindale became President of Proforma Inc.
2004-12-31	Alan Chippindale's tenure as President of Proforma Inc. ended.
2008-01-01	Alan Chippindale became Chief Business Development Officer of BrandAlliance Inc.
2010-08-01	Sarah L. Cummins served as Vice President at Vineyard Vines LLC.
2012-10-31	Sarah L. Cummins' tenure as Vice President at Vineyard Vines LLC ended.
2013-01-01	Sarah L. Cummins became Head of Business Development & Strategic Partnerships at New York Road Runners, Inc.
2015-11-01	David Browner became the Company's Accounting Manager.
2021-07-01	David Browner became the Company's Controller.
2021-07-13	Employment agreements with Andrew Shape and Andrew Stranberg dated.
2021-07-20	Independent Director Agreements dated.
2021-09-14	Stran & Company, Inc. Amended and Restated 2021 Equity Incentive Plan established.
2021-11-01	Alan Chippindale became a director of the Company.
2021-11-08	Employment agreements with Andrew Shape and Andrew Stranberg became effective.
2021-11-12	Andrew Shape and Andrew Stranberg were awarded stock options.
2021-12-02	Audibert Consulting Agreement dated.
2022-03-11	Compensation Committee determined performance conditions met for JCA's option vesting and issuance of 20,000 shares.
2022-07-28	David Browner appointed as the Company's Interim Chief Financial Officer.
2022-07-29	David Browner's salary increased to $200,000.
2023-02-01	Sarah L. Cummins served as an Operating Partner at Isos7 Sports.
2023-03-06	Innovative Genetics Packaging Agreement and Statement of Work No. 1 became effective; Mr. Tani executed a Guaranty.
2023-03-27	David Browner appointed as the Company's Chief Financial Officer; Insider Trading Policy adopted.
2023-04-14	Browner Employment Agreement approved and entered; A&R Audibert Consulting Agreement approved and entered; Mr. Browner granted stock option for 100,000 shares; JCA granted 46,511 restricted shares and stock option for 180,000 shares.
2023-06-23	Alan Chippindale purchased 8,000 shares of common stock on the open market.
2023-06-28	Statement of Work #2 with Kapstone Partners, LLC entered.
2023-06-29	Rights to all equity awards granted to JCA distributed or transferred to Mr. Audibert; Andrew Stranberg purchased 2,695.707 shares of common stock on the open market.
2023-06-30	Andrew Stranberg purchased 9,934.436 shares of common stock on the open market.
2023-07-01	Services under SOW #2 with Kapstone Partners, LLC began.
2023-08-28	Andrew Stranberg purchased 10,560 shares of common stock on the open market.
2023-09-07	Ashley L. Marshall purchased 760 shares of common stock on the open market.
2023-09-30	Services under SOW #2 with Kapstone Partners, LLC ended.
2023-10-01	Services under SOW #3 with Kapstone Partners, LLC began.
2023-10-03	Statement of Work #3 with Kapstone Partners, LLC entered.
2023-11-02	Board adopted the Company's Clawback Policy.
2023-12-11	Employment letter agreement with Ian Wall dated.
2023-12-29	Services under SOW #3 with Kapstone Partners, LLC ended.
2023-12-31	Fiscal year ended.
2024-01-01	Company granted Mr. Browner a second stock option for 100,000 shares; Company granted Mr. Audibert a second stock option for 180,000 shares.
2024-01-02	Ian Wall granted an option to purchase 15,000 shares of common stock and became entitled to awards of options to purchase up to 100,000 shares.
2024-01-29	Ian Wall awarded option to purchase 15,000 shares at $1.46 per share; 23,043 shares of common stock awarded to Sarah L. Cummins under the Plan.
2024-02-15	Compensation Committee certified attainment of performance conditions for Mr. Browner's cash bonus, stock grant, and option vesting for FY2023; Compensation Committee certified vesting of 2,339 restricted shares for JCA; Compensation Committee awarded discretionary bonuses to JCA.
2024-03-25	Andrew Shape orally waived all outstanding accrued interest upon prior-year commissions payable to him.
2024-05-03	SEC Order Instituting Public Administrative and Cease-and-Desist Proceedings against BF Borgers CPA PC.
2024-05-13	Company dismissed BF Borgers CPA PC as its independent registered public accounting firm.
2024-05-01	Mark Charles Adams served on the board of directors of DAP Health Inc.
2024-06-15	Company engaged Marcum LLP as its new independent registered public accounting firm.
2024-07-01	Sarah L. Cummins served as Senior Vice President, Global Partnerships at WTA Ventures LLC.
2024-08-01	Brian M. Posner served as a director of Firefly Neuroscience, Inc.
2024-10-01	Brian M. Posner began providing financial and accounting consulting services to electroCore.
2024-11-01	CBIZ CPAs P.C. acquired the attest business of Marcum LLP.
2024-11-08	Initial term of Shape and Stranberg Employment Agreements ended and automatically renewed for an additional one-year term.
2024-12-31	Fiscal year ended; balance owed by Innovative Genetics was $1,001,000, with 8% annual interest accruing.
2025-01-22	Annual Report on Form 10-K/A (Amendment No. 1) for FY2023 filed with the SEC.
2025-03-19	Compensation Committee approved discretionary cash bonuses of $50,000 to Mr. Shape, $25,000 to Mr. Browner, and $25,000 to Mr. Audibert.
2025-04-14	Annual Report on Form 10-K for FY2024 filed with the SEC; initial term of Browner Employment Agreement ended and automatically extended for an additional year.
2025-04-30	Marcum LLP resigned as the Company's independent registered public accounting firm; CBIZ CPAs P.C. was engaged as the Company's independent registered public accounting firm.
2025-05-02	Marcum LLP's letter filed as Exhibit 16.1 to Current Report on Form 8-K.
2025-05-27	Record Date for the Combined 2024 and 2025 Annual Meeting of Stockholders.
2025-06-01	Travis McCourt, Alejandro Tani, and Ashley L. Marshall ceased being directors of the Company.
2025-06-20	Mark Charles Adams and Sarah L. Cummins became directors; Company entered into Independent Director Agreements with Mr. Adams, Mr. Chippindale, and Ms. Cummins; Company granted restricted shares and stock options to Mr. Adams, Mr. Chippindale, and Ms. Cummins.
2025-07-08	Brian M. Posner became a director; Company entered into Independent Director Agreement with Brian M. Posner; Company granted restricted shares and stock option to Mr. Posner.
2025-07-09	Date for beneficial ownership information.
2025-07-11	Approximate date proxy statement and accompanying materials intended to be sent or made available to stockholders; Date of proxy statement.
2025-07-25	Combined 2024 and 2025 Annual Meeting of Stockholders to be held.
2026-02-05	Deadline for stockholder proposals to be included in the 2026 Annual Meeting proxy statement under Rule 14a-8.
2026-03-27	Earliest date for stockholder notice of proposals or director nominations for the 2026 Annual Meeting (per Bylaws).
2026-04-16	Deadline for public announcement of director nominees or board size increase for the 2026 Annual Meeting.
2026-04-26	Latest date for stockholder notice of proposals or director nominations for the 2026 Annual Meeting (per Bylaws).
2026-05-26	Deadline for universal proxy notice for the 2026 Annual Meeting.

Recommendation

sell

Keywords

Stran & Company, SEC filing, proxy statement, corporate governance, director election, auditor ratification, internal controls, financial reporting, material weaknesses, related party transactions, executive compensation, Nasdaq, DEF 14A

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.